CHINA SXT PHARMACEUTICALS IN (SXTC)
VGG2161P1403 - Common Stock
We assign a fundamental rating of 1 out of 10 to SXTC. SXTC was compared to 198 industry peers in the Pharmaceuticals industry. SXTC has a bad profitability rating. Also its financial health evaluation is rather negative. SXTC has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year SXTC has reported negative net income.
SXTC had a negative operating cash flow in the past year.
SXTC had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: SXTC reported negative operating cash flow in multiple years.
1.2 Ratios
With a Return On Assets value of -96.90%, SXTC is not doing good in the industry: 81.03% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -278.47%, SXTC is doing worse than 77.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -96.9% | ||
| ROE | -278.47% | ||
| ROIC | N/A |
ROA(3y)-15.05%
ROA(5y)-16.75%
ROE(3y)-30.85%
ROE(5y)-37.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 36.97%, SXTC is in line with its industry, outperforming 54.87% of the companies in the same industry.
SXTC's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SXTC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 36.97% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-25.28%
GM growth 5Y-14.73%
2. Health
2.1 Basic Checks
SXTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
SXTC has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SXTC has been increased compared to 5 years ago.
SXTC has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -5.62, we must say that SXTC is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -5.62, SXTC is not doing good in the industry: 65.13% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.07 indicates that SXTC is not too dependend on debt financing.
SXTC's Debt to Equity ratio of 0.07 is in line compared to the rest of the industry. SXTC outperforms 49.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.62 |
ROIC/WACCN/A
WACC2.68%
2.3 Liquidity
SXTC has a Current Ratio of 1.47. This is a normal value and indicates that SXTC is financially healthy and should not expect problems in meeting its short term obligations.
SXTC has a worse Current ratio (1.47) than 76.41% of its industry peers.
A Quick Ratio of 1.41 indicates that SXTC should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.41, SXTC is doing worse than 69.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.47 | ||
| Quick Ratio | 1.41 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 56.19% over the past year.
The Revenue for SXTC has decreased by -38.86% in the past year. This is quite bad
The Revenue for SXTC have been decreasing by -22.44% on average. This is quite bad
EPS 1Y (TTM)56.19%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-29.86%
Revenue 1Y (TTM)-38.86%
Revenue growth 3Y-27.46%
Revenue growth 5Y-22.44%
Revenue growth Q2Q-22.35%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
SXTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
SXTC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CHINA SXT PHARMACEUTICALS IN
NASDAQ:SXTC (5/6/2024, 7:00:00 PM)
After market: 0.9993 +0.02 (+2.1%)0.9787
+0.02 (+1.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap557.86K
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -96.9% | ||
| ROE | -278.47% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 36.97% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.47 | ||
| Quick Ratio | 1.41 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)56.19%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-38.86%
Revenue growth 3Y-27.46%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y